Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMAGlobeNewsWire • 12/30/24
Novartis must face claims it paid kickbacks to promote MS drug, US appeals court rulesReuters • 12/27/24
Buy 5 Large-Cap Laggards of 2024 Likely to Surge in the Near TermZacks Investment Research • 12/23/24
The Zacks Analyst Blog Mastercard, The Procter & Gamble, Novartis AG, IDT and GSI TechnologyZacks Investment Research • 12/13/24
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancerGlobeNewsWire • 12/10/24
Novartis Announces Positive Results From Late-Stage Study on FabhaltaZacks Investment Research • 12/09/24
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CMLGlobeNewsWire • 12/08/24
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapyGlobeNewsWire • 12/06/24
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 BillionZacks Investment Research • 12/03/24
Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide ForwardSeeking Alpha • 12/02/24
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's ProgramBenzinga • 12/02/24
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease ProgramPRNewsWire • 12/02/24
EC Approves NVS' Kisqali for a Broad Population in Early Breast CancerZacks Investment Research • 11/28/24